{
    "clinical_study": {
        "@rank": "158050", 
        "arm_group": [
            {
                "arm_group_label": "LY2605541-Part A", 
                "arm_group_type": "Experimental", 
                "description": "1.42 units per kilogram (U/kg) of LY2605541 given once daily (QD) for 1 day, subcutaneously (SQ) in 1 of 4 treatment periods."
            }, 
            {
                "arm_group_label": "Insulin Lispro-Part A", 
                "arm_group_type": "Active Comparator", 
                "description": "Single dose 0.36 U/kg of insulin lispro given QD for 1 day, SQ in 1 of 4 treatment periods."
            }, 
            {
                "arm_group_label": "LY2605541/Lispro Mix 1-Part A", 
                "arm_group_type": "Experimental", 
                "description": "Single dose 0.54  U/kg of LY2605541 and 0.36 U/kg insulin lispro mixture given QD for 1 day, SQ in 1 of 4 treatment periods."
            }, 
            {
                "arm_group_label": "LY2605541/Lispro Mix 2-Part A", 
                "arm_group_type": "Experimental", 
                "description": "Single dose 1.42 U/kg of LY2605541 and 0.36 insulin lispro mixture given QD for 1 day, SQ in 1 of 4 treatment periods."
            }, 
            {
                "arm_group_label": "Insulin Lispro-Part B", 
                "arm_group_type": "Active Comparator", 
                "description": "0.18 U/kg insulin lispro given twice daily (BID) for 1 day, SQ in 1 of 4 treatment periods.  Part B is contingent on data from Part A."
            }, 
            {
                "arm_group_label": "LY2605541/Lispro Mix-Part B", 
                "arm_group_type": "Experimental", 
                "description": "0.71 U/kg LY2605541 and 0.18 U/kg insulin lispro mixture given BID for 1 day, SQ in 1 of 4 treatment periods.  Part B is contingent on data from Part A."
            }, 
            {
                "arm_group_label": "LY2605541 QD-Part B", 
                "arm_group_type": "Experimental", 
                "description": "0.54 U/kg of LY2605541 given QD for 1 day, SQ in 1 of 4 treatment periods.  Part B is contingent on data from Part A."
            }, 
            {
                "arm_group_label": "LY2605541 BID-Part B", 
                "arm_group_type": "Experimental", 
                "description": "0.71 U/kg  of LY2605541 given BID for 1 day SQ in 1 of 4 treatment periods.  Part B is contingent on data from Part A."
            }
        ], 
        "brief_summary": {
            "textblock": "The main purpose of this study is to evaluate how the body absorbs and removes LY2605541,\n      insulin lispro, and a mixture of both from the blood.  The study has two parts.\n      Participants may enroll in only one part.  Each part has four treatment periods in a fixed\n      order.  The study  will last approximately 8 weeks, not including screening.  Screening is\n      required within 28 days prior to the start of the study."
        }, 
        "brief_title": "A Study of LY2605541 and Insulin Lispro Mixture in Healthy Participants", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy Volunteers", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Are not of child-bearing potential\n\n          -  Have a body mass index (BMI) between 18 and 29.9 kilograms per meter squared\n             (kg/m^2), inclusive\n\n          -  Are nonsmokers or have not smoked for at least 2 months prior to entering the study\n\n        Exclusion Criteria:\n\n          -  Have known allergies to insulin or its excipients, or related drugs, or history of\n             relevant allergic reactions of any origin\n\n          -  Have a history of first-degree relatives known to have diabetes mellitus\n\n          -  Have used systemic glucocorticoids within 3 months prior to entry into the study\n\n          -  Have donated blood or had a blood loss of 450 milliliter (mL) within 1 month prior to\n             study enrollment"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01871493", 
            "org_study_id": "14833", 
            "secondary_id": "I6O-FW-BHBA"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "LY2605541-Part A", 
                    "LY2605541/Lispro Mix 1-Part A", 
                    "LY2605541/Lispro Mix 2-Part A", 
                    "LY2605541/Lispro Mix-Part B", 
                    "LY2605541 QD-Part B", 
                    "LY2605541 BID-Part B"
                ], 
                "description": "Administered subcutaneous (SQ)", 
                "intervention_name": "LY2605541", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Insulin Lispro-Part A", 
                    "LY2605541/Lispro Mix 1-Part A", 
                    "LY2605541/Lispro Mix 2-Part A", 
                    "Insulin Lispro-Part B", 
                    "LY2605541/Lispro Mix-Part B"
                ], 
                "description": "Administered SQ", 
                "intervention_name": "Insulin Lispro", 
                "intervention_type": "Drug", 
                "other_name": "Humalog"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Insulin LISPRO", 
                "Insulin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "March 4, 2014", 
        "location": {
            "contact": {
                "last_name": "Eli Lilly"
            }, 
            "facility": {
                "address": {
                    "city": "Singapore", 
                    "country": "Singapore", 
                    "zip": "117597"
                }, 
                "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Singapore"
        }, 
        "number_of_arms": "8", 
        "official_title": "A Phase 1 Study to Evaluate the Pharmacokinetics of LY2605541 Injection and Insulin Lispro Injection Administered as Mixture or as Individual Components in Healthy Subjects", 
        "overall_contact": {
            "last_name": "There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or", 
            "phone": "1-317-615-4559"
        }, 
        "overall_official": {
            "affiliation": "Eli Lilly and Company", 
            "last_name": "Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Singapore: Health Sciences Authority", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Pharmacokinetics (PK): Time to Reach Peak Concentration (tmax) of LY2605541 and Insulin Lispro", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose up to 216 hours post-dose"
            }, 
            {
                "measure": "Pharmacokinetics (PK): Maximum Drug Concentration (Cmax) of LY2605541 and Insulin Lispro", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose up to 216 hours post-dose"
            }, 
            {
                "measure": "Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC0-\u221e) of LY2605541 and Insulin Lispro", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose up to 216 hours post-dose"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01871493"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Maximum Glucose Infusion Rate (Rmax)", 
                "safety_issue": "No", 
                "time_frame": "Predose up to 32 hours post clamp procedure in all treatment periods"
            }, 
            {
                "measure": "Total Glucose Infused Over Clamp Duration (Gtot)", 
                "safety_issue": "No", 
                "time_frame": "Predose up to 32 hours post clamp procedure in all treatment periods"
            }
        ], 
        "source": "Eli Lilly and Company", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Eli Lilly and Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}